Lipocine

LPCN · NASDAQ

$1.62+$0.09 (+5.88%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.53

Latest news

NewsOct 7, 12:02 PM ETAvi Kapoor
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
NewsOct 7, 10:44 AM ETVandana Singh
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
NewsOct 7, 9:52 AM ETAvi Kapoor
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
NewsOct 7, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseOct 7, 8:00 AM ETPRNewswire
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
NewsOct 7, 6:25 AM ET
Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males
Press releaseSep 14, 8:00 AM ETPRNewswire
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Press releaseSep 10, 8:00 AM ETPRNewswire
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Press releaseAug 4, 8:00 AM ETPRNewswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Press releaseAug 3, 8:00 AM ETPRNewswire
Lipocine Appoints Michael J. Grissinger to Board of Directors
Press releaseJun 4, 8:00 AM ETPRNewswire
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Press releaseMay 19, 8:00 AM ETPRNewswire
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Press releaseMay 19, 4:00 AM ETGlobe Newswire
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Press releaseMay 18, 8:00 AM ETPRNewswire
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Press releaseMay 7, 4:05 PM ETPRNewswire
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
NewsApr 6, 2:06 PM ETLekha Gupta
What's Going On With Carvana Stock Monday?
NewsApr 2, 1:30 PM ETAvi Kapoor
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
NewsApr 2, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsApr 2, 10:44 AM ETAvi Kapoor
Nasdaq Down 1%; US Initial Jobless Claims Fall
Press releaseApr 2, 8:00 AM ETPRNewswire
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
NewsMar 31, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 10, 8:00 AM ETPRNewswire
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Press releaseFeb 18, 8:00 AM ETPRNewswire
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Press releaseJan 20, 8:00 AM ETPRNewswire
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Press releaseJan 19, 12:20 PM ETGlobe Newswire
2026 Asset Growth: Why Federal Compliance Is the New Metric
Press releaseJan 12, 8:00 AM ETPRNewswire
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Press releaseDec 16, 8:00 AM ETPRNewswire
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Press releaseNov 18, 8:00 AM ETPRNewswire
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Press releaseNov 6, 8:00 AM ETPRNewswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Press releaseNov 4, 8:00 AM ETPRNewswire
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Press releaseSep 30, 8:00 AM ETPRNewswire
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Press releaseSep 5, 4:30 PM ETPRNewswire
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Press releaseAug 26, 8:00 AM ETPRNewswire
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Press releaseAug 5, 8:00 AM ETPRNewswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
NewsMay 19, 8:09 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsMay 12, 1:07 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsMay 8, 8:10 AM ET
Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Nasdaq Falls Over 100 Points; US Crude Inventories Decline

Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada

Dow Tumbles 350 Points; Constellation Brands Earnings Top Views

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

What's Going On With Carvana Stock Monday?

Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results

12 Health Care Stocks Moving In Thursday's Intraday Session

Nasdaq Down 1%; US Initial Jobless Claims Fall

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

12 Health Care Stocks Moving In Tuesday's After-Market Session

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

2026 Asset Growth: Why Federal Compliance Is the New Metric

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate